Manami Kinjo1, Kazuki Masuda2, Yu Nakamura2, Satoru Taguchi2, Mitsuhiro Tambo2, Hiroshi Fukuhara2. 1. Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa Mitaka-shi, Tokyo, 181-8611, Japan. Kinjo_1702@yahoo.co.jp. 2. Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa Mitaka-shi, Tokyo, 181-8611, Japan.
Abstract
INTRODUCTION AND HYPOTHESIS: We aimed to determine whether the presence of metabolic syndrome (MS) affects the efficacy of mirabegron in treatment-naïve women with overactive bladder (OAB). METHODS: Women being treated with mirabegron 50 mg were allocated to MS and non-MS groups, and the efficacy of treatment of OAB was compared using the OAB symptom score (OABSS) and a 3-day voiding diary before and 12 weeks after starting treatment. The Wilcoxon signed-rank and Mann-Whitney U tests and multivariate logistic regression were used for statistical analyses, and a p-value < 0.05 was considered to represent statistical significance. RESULTS: Of the 197 patients who completed the trial, 43 (23.9%) had MS. After 12 weeks of mirabegron treatment, both the MS and non-MS groups showed significant improvements in OABSS score, the number of incontinence episodes/24 h, the number of micturition episodes/24 h, and the number of episodes of urgency/24 h. The factors associated with clinically important differences in OABSS were the presence of hyperglycemia (odds ratio 2.43, 95% confidence interval [CI] 1.05-5.60) and OABSS score at baseline (odds ratio 1.23, 95% CI 1.09-1.39). CONCLUSIONS: Mirabegron is effective in patients with and without MS, and comorbid hyperglycemia and severe OAB symptoms before treatment are predictors of the efficacy of mirabegron treatment.
INTRODUCTION AND HYPOTHESIS: We aimed to determine whether the presence of metabolic syndrome (MS) affects the efficacy of mirabegron in treatment-naïve women with overactive bladder (OAB). METHODS: Women being treated with mirabegron 50 mg were allocated to MS and non-MS groups, and the efficacy of treatment of OAB was compared using the OAB symptom score (OABSS) and a 3-day voiding diary before and 12 weeks after starting treatment. The Wilcoxon signed-rank and Mann-Whitney U tests and multivariate logistic regression were used for statistical analyses, and a p-value < 0.05 was considered to represent statistical significance. RESULTS: Of the 197 patients who completed the trial, 43 (23.9%) had MS. After 12 weeks of mirabegron treatment, both the MS and non-MS groups showed significant improvements in OABSS score, the number of incontinence episodes/24 h, the number of micturition episodes/24 h, and the number of episodes of urgency/24 h. The factors associated with clinically important differences in OABSS were the presence of hyperglycemia (odds ratio 2.43, 95% confidence interval [CI] 1.05-5.60) and OABSS score at baseline (odds ratio 1.23, 95% CI 1.09-1.39). CONCLUSIONS: Mirabegron is effective in patients with and without MS, and comorbid hyperglycemia and severe OAB symptoms before treatment are predictors of the efficacy of mirabegron treatment.
Authors: Holly E Richter; C L Amundsen; S W Erickson; J E Jelovsek; Y Komesu; C Chermansky; H S Harvie; M Albo; D Myers; W T Gregory; D Wallace Journal: J Urol Date: 2017-05-10 Impact factor: 7.450
Authors: Linda Cardozo; Sender Herschorn; Robert Snijder; Emad Siddiqui; Christopher R Chapple Journal: Int Urogynecol J Date: 2016-09-07 Impact factor: 2.894
Authors: Christopher R Chapple; Francisco Cruz; Linda Cardozo; David Staskin; Sender Herschorn; Nurul Choudhury; Matthias Stoelzel; John Heesakkers; Emad Siddiqui Journal: Eur Urol Date: 2019-10-18 Impact factor: 20.096
Authors: Vik Khullar; Chris C Sexton; Christine L Thompson; Ian Milsom; Caty Ebel Bitoun; Karin S Coyne Journal: Neurourol Urodyn Date: 2013-06-18 Impact factor: 2.696